Can-Fite BioPharma Ltd. (TLV: CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA1.700
-0.100 (-5.56%)
Dec 19, 2024, 5:24 PM IDT
Can-Fite BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.67 | 0.74 | 0.81 | 0.85 | 0.76 | 2.03 | Upgrade
|
| Revenue Growth (YoY) | -15.89% | -8.27% | -5.04% | 11.80% | -62.45% | -46.81% | Upgrade
|
| Gross Profit | 0.67 | 0.74 | 0.81 | 0.85 | 0.76 | 2.03 | Upgrade
|
| Selling, General & Admin | 3.01 | 2.96 | 3.14 | 3.85 | 2.95 | 3.06 | Upgrade
|
| Research & Development | 5.45 | 5.98 | 7.76 | 9.85 | 11.95 | 10.98 | Upgrade
|
| Operating Expenses | 8.46 | 8.94 | 10.91 | 13.7 | 14.9 | 14.04 | Upgrade
|
| Operating Income | -7.79 | -8.2 | -10.1 | -12.84 | -14.14 | -12.01 | Upgrade
|
| Interest Expense | - | - | - | - | -0.36 | -0.43 | Upgrade
|
| Interest & Investment Income | 0.37 | 0.51 | 0.22 | 0.02 | 0.04 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.05 | 0.06 | 0.03 | -0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -7.38 | -7.65 | -9.94 | -12.78 | -14.45 | -12.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.01 | 0.01 | -0.23 | 0.16 | 0.01 | -0.21 | Upgrade
|
| Pretax Income | -7.37 | -7.63 | -10.17 | -12.62 | -14.44 | -12.63 | Upgrade
|
| Earnings From Continuing Operations | -7.37 | -7.63 | -10.17 | -12.62 | -14.44 | -12.63 | Upgrade
|
| Net Income | -7.37 | -7.63 | -10.17 | -12.62 | -14.44 | -12.63 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 2.59 | 0.72 | - | Upgrade
|
| Net Income to Common | -7.37 | -7.63 | -10.17 | -15.21 | -15.16 | -12.63 | Upgrade
|
| Shares Outstanding (Basic) | 1,588 | 1,278 | 816 | 553 | 358 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 1,588 | 1,278 | 816 | 553 | 358 | 86 | Upgrade
|
| Shares Change (YoY) | 57.39% | 56.71% | 47.49% | 54.31% | 317.19% | 120.84% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.01 | -0.03 | -0.04 | -0.15 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.01 | -0.03 | -0.04 | -0.15 | Upgrade
|
| Free Cash Flow | -7.44 | -8.44 | -10.81 | -9.87 | -12.09 | -11.09 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.02 | -0.03 | -0.13 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -1168.37% | -1102.96% | -1246.42% | -1505.51% | -1853.08% | -590.90% | Upgrade
|
| Profit Margin | -1105.10% | -1027.46% | -1255.93% | -1782.53% | -1986.63% | -621.31% | Upgrade
|
| Free Cash Flow Margin | -1114.69% | -1136.20% | -1334.57% | -1156.98% | -1584.40% | -545.62% | Upgrade
|
| EBITDA | -7.79 | -8.18 | -10.08 | -12.83 | -14.13 | -11.99 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| EBIT | -7.79 | -8.2 | -10.1 | -12.84 | -14.14 | -12.01 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.